Pfizer Financial Statements (PFE)
|
|
|
|
Report date
|
|
|
27.02.2020 |
25.02.2021 |
24.02.2022 |
23.02.2023 |
22.02.2024 |
|
04.11.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
51 750 |
41 908 |
81 288 |
100 330 |
58 496 |
|
60 743 |
|
Operating Income, bln rub |
|
|
15 137 |
10 630 |
24 833 |
40 030 |
3 359 |
|
15 927 |
|
EBITDA, bln rub |
? |
|
18 853 |
13 168 |
30 793 |
41 031 |
9 557 |
|
21 861 |
|
Net profit, bln rub |
? |
|
16 273 |
7 020 |
21 979 |
31 372 |
2 119 |
|
10 706 |
|
|
OCF, bln rub |
? |
|
12 588 |
14 403 |
32 580 |
29 267 |
8 700 |
|
6 023 |
|
CAPEX, bln rub |
? |
|
2 594 |
2 791 |
2 711 |
3 236 |
3 907 |
|
1 992 |
|
FCF, bln rub |
? |
|
9 994 |
11 612 |
29 869 |
26 031 |
4 793 |
|
4 031 |
|
Dividend payout, bln rub
|
|
|
8 043 |
8 440 |
8 729 |
8 983 |
9 247 |
|
7 132 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
49.4% |
120.2% |
39.7% |
28.6% |
436.4% |
|
66.6% |
|
|
OPEX, bln rub |
|
|
27 610 |
24 456 |
30 232 |
28 714 |
25 450 |
|
25 441 |
|
Cost of production, bln rub |
|
|
10 219 |
8 692 |
30 821 |
34 344 |
29 687 |
|
18 063 |
|
R&D, bln rub |
|
|
8 650 |
9 405 |
13 829 |
11 428 |
10 679 |
|
10 247 |
|
Interest expenses, bln rub |
|
|
1 574 |
1 449 |
1 291 |
1 238 |
2 209 |
|
3 141 |
|
|
Assets, bln rub |
|
|
167 488 |
154 229 |
181 477 |
197 206 |
226 501 |
|
219 476 |
|
Net Assets, bln rub |
? |
|
63 143 |
63 238 |
77 201 |
95 661 |
89 014 |
|
92 286 |
|
Debt, bln rub |
|
|
52 145 |
38 274 |
36 998 |
34 870 |
75 041 |
|
66 617 |
|
Cash, bln rub |
|
|
9 830 |
12 221 |
31 069 |
22 732 |
12 690 |
|
8 860 |
|
Net debt, bln rub |
|
|
42 315 |
26 053 |
5 929 |
12 138 |
62 351 |
|
57 757 |
|
|
Ordinary share price, rub |
|
|
37.1 |
36.8 |
59.1 |
51.2 |
28.8 |
|
30.5 |
|
Number of ordinary shares, mln |
|
|
5 569 |
5 555 |
5 601 |
5 608 |
5 643 |
|
5 667 |
|
|
Market cap, bln rub |
|
|
206 833 |
204 480 |
330 739 |
287 354 |
162 462 |
|
172 957 |
|
EV, bln rub |
? |
|
249 148 |
230 533 |
336 668 |
299 492 |
224 813 |
|
230 714 |
|
Book value, bln rub |
|
|
-30 879 |
-14 811 |
2 847 |
916 |
-43 669 |
|
-36 270 |
|
|
EPS, rub |
? |
|
2.92 |
1.26 |
3.92 |
5.59 |
0.38 |
|
1.89 |
|
FCF/share, rub |
|
|
1.79 |
2.09 |
5.33 |
4.64 |
0.85 |
|
0.71 |
|
BV/share, rub |
|
|
-5.54 |
-2.67 |
0.51 |
0.16 |
-7.74 |
|
-6.40 |
|
|
EBITDA margin, % |
? |
|
36.4% |
31.4% |
37.9% |
40.9% |
16.3% |
|
36.0% |
|
Net margin, % |
? |
|
31.4% |
16.8% |
27.0% |
31.3% |
3.62% |
|
17.6% |
|
FCF yield, % |
? |
|
4.83% |
5.68% |
9.03% |
9.06% |
2.95% |
|
2.33% |
|
ROE, % |
? |
|
25.8% |
11.1% |
28.5% |
32.8% |
2.38% |
|
11.6% |
|
ROA, % |
? |
|
9.72% |
4.55% |
12.1% |
15.9% |
0.94% |
|
4.88% |
|
|
P/E |
? |
|
12.7 |
29.1 |
15.0 |
9.16 |
76.7 |
|
16.2 |
|
P/FCF |
|
|
20.7 |
17.6 |
11.1 |
11.0 |
33.9 |
|
42.9 |
|
P/S |
? |
|
4.00 |
4.88 |
4.07 |
2.86 |
2.78 |
|
2.85 |
|
P/BV |
? |
|
-6.70 |
-13.8 |
116.2 |
313.7 |
-3.72 |
|
-4.77 |
|
EV/EBITDA |
? |
|
13.2 |
17.5 |
10.9 |
7.30 |
23.5 |
|
10.6 |
|
Debt/EBITDA |
|
|
2.24 |
1.98 |
0.19 |
0.30 |
6.52 |
|
2.64 |
|
|
R&D/CAPEX, % |
|
|
333.5% |
337.0% |
510.1% |
353.2% |
273.3% |
|
514.4% |
|
|
CAPEX/Revenue, % |
|
|
5.01% |
6.66% |
3.34% |
3.23% |
6.68% |
|
3.28% |
|
| Pfizer shareholders |
